Key result
Early treatment with Edoxaban in patients with acute cardioembolic stroke resulted in 0 symptomatic intracranial bleedings, 2 gastrointestinal major bleedings, and 11 minor bleedings at 3 months.
Why the study?
Data were lacking regarding the optimal timing to initiate oral anticoagulation after acute stroke in patients with non-valvular atrial fibrillation.
Does early treatment with edoxaban prevent recurrent stroke without increasing symptomatic bleeding in patients with acute cardioembolic stroke and non-valvular atrial fibrillation?
Observational (n=75)
Does early treatment with edoxaban prevent recurrent stroke without increasing symptomatic bleeding in patients with acute cardioembolic stroke and non-valvular atrial fibrillation?
Early administration of edoxaban after acute cardioembolic stroke in patients with non-valvular atrial fibrillation appears safe, with no symptomatic intracranial bleeding or recurrent stroke observed at 90 days.
No takes yet. Share an insight, caveat, or question.
Low bleeding rates observed with early Edoxaban post-acute cardioembolic stroke; leaves open practice change pending randomized confirmation.
Frisullo et al. (2020) conducted an observational in Ischemic Stroke and Non-valvular Atrial Fibrillation (n=75). Early treatment with Edoxaban was evaluated on Occurrence of symptomatic bleedings within 90 days from acute cardioembolic stroke. Early treatment with Edoxaban in patients with acute cardioembolic stroke resulted in 0 symptomatic intracranial bleedings, 2 gastrointestinal major bleedings, and 11 minor bleedings at 3 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: